文献速递糖尿病

埃格列净延缓2型糖尿病患者胰岛素启动并减少胰岛素剂量需求:VERTIS CV研究分析

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

VERTIS CV研究评估埃格列净在2型糖尿病合并动脉粥样硬化性心血管疾病患者中的心血管安全性。分析显示,在基线未使用胰岛素的4348例患者中,埃格列净5 mg和15 mg较安慰剂显著降低胰岛素启动风险(HR分别为0.70和0.64),并延迟胰岛素启动时间;在基线使用胰岛素的3898例患者中,埃格列净显著降低胰岛素剂量增加≥20%的风险(HR分别为0.62和0.51),且未增加低血糖事件。

要点

  • 在基线未使用胰岛素的患者中,埃格列净5 mg和15 mg较安慰剂显著降低胰岛素启动风险,HR分别为0.70和0.64。
  • 埃格列净5 mg和15 mg较安慰剂延迟达到10%累积胰岛素启动率的时间分别为399天和669天。
  • 在基线使用胰岛素的患者中,埃格列净5 mg和15 mg较安慰剂显著降低胰岛素剂量增加≥20%的风险,HR分别为0.62和0.51。

核心结论

  • 在VERTIS CV患者中,埃格列净较安慰剂降低胰岛素启动可能性,延迟胰岛素启动时间最多约1.8年,并减少胰岛素剂量需求,且不增加低血糖事件。

研究设计与样本

  • VERTIS CV研究评估埃格列净在2型糖尿病合并动脉粥样硬化性心血管疾病患者中的心血管安全性;患者每日一次接受埃格列净5 mg、15 mg或安慰剂,平均随访3.5年。

主要发现

  • VERTIS CV中2型糖尿病平均病程13.0年,糖化血红蛋白8.2%。
  • 在4348例(53%)基线未使用胰岛素的患者中,埃格列净5 mg较安慰剂显著降低胰岛素启动可能性(HR 0.70,95% CI 0.58-0.84),埃格列净15 mg较安慰剂显著降低(HR 0.64,95% CI 0.53-0.78)。
  • 埃格列净延迟胰岛素启动时间;较安慰剂达到10%累积新胰岛素启动率估计延迟:埃格列净5 mg为399天,埃格列净15 mg为669天。
  • 在3898例(47%)基线使用胰岛素的患者中,埃格列净5 mg较安慰剂显著降低胰岛素剂量增加≥20%的可能性(HR 0.62,95% CI 0.52-0.75),埃格列净15 mg较安慰剂显著降低(HR 0.51,95% CI 0.41-0.62)。
  • 埃格列净治疗未增加低血糖事件发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: The aim of these analyses was to assess the insulin requirements of VERTIS CV patients over the trial duration. METHODS: Patients received ertugliflozin 5 mg, 15 mg, or placebo once daily; mean follow-up was 3.5 years. Time to insulin initiation in patients who were insulin naïve at baseline, change in insulin dose in patients receiving baseline insulin, and hypoglycemia incidence in both patient groups were assessed. RESULTS: In VERTIS CV, mean duration of type 2 diabetes was 13.0 years; glycated hemoglobin was 8.2%. Among 4348 (53%) insulin-naïve patients, the likelihood of insulin initiation was significantly reduced with ertugliflozin vs placebo (ertugliflozin 5 mg: hazard ratio [HR] 0.70, 95% CI 0.58-0.84; ertugliflozin 15 mg: HR 0.64, 95% CI 0.53-0.78). Time to insulin initiation was delayed with ertugliflozin; the estimated delay in reaching a 10% cumulative incidence of new insulin initiations vs placebo was 399 days with ertugliflozin 5 mg and 669 days with ertugliflozin 15 mg. Among 3898 (47%) patients receiving baseline insulin, the likelihood of requiring a ≥20% increase in insulin dose was significantly reduced with ertugliflozin vs placebo (ertugliflozin 5 mg: HR 0.62, 95% CI 0.52-0.75; ertugliflozin 15 mg: HR 0.51, 95% CI 0.41-0.62). The incidence of hypoglycemia events was not increased with ertugliflozin treatment. CONCLUSION: In VERTIS CV patients, ertugliflozin reduced the likelihood of insulin initiation, delayed the time to insulin initiation by up to ∼1.8 years, and reduced insulin dose requirements vs placebo, without increasing hypoglycemia events.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack S, Frederich R, Liu J, et al. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. J Clin Endocrinol Metab. 2023. PMID: 36702781. doi:10.1210/clinem/dgac764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。